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Few studies have compared treatment patterns, healthcare resource utilization (HRU), and costs in patients with
metastatic breast cancer (mBC) receiving HER2 directed therapy. This study evaluated these outcomes in patients
receiving trastuzumab or lapatinib. Adult women with mBC, who were initiated on trastuzumab or lapatinib, on or
after March 13, 2007, were selected from the US-based PharMetrics® Integrated Database (2000–2011). Patients were
required to be continuously enrolled in their healthcare plan for ≥6 months prior to and ≥30 days following
trastuzumab or lapatinib initiation. Trastuzumab or lapatinib discontinuation rates (defined as a gap ≥45 consecutive
days) were compared using multivariate Cox proportional-hazards models. HRU and monthly healthcare cost
differences were estimated using multivariate negative binomial regression models and generalized linear models,
respectively. Among the 643 patients who met the inclusion criteria, 381 and 262 patients were included in the
trastuzumab and lapatinib groups, respectively. The majority of the 262 patients receiving lapatinib previously
received trastuzumab (N = 171 [65.3%]). After adjustment for potential confounders, when compared to trastuzumab
patients, lapatinib patients had a higher rate of treatment discontinuation (hazard ratio [HR] = 1.57; P < 0.001), a
higher rate of outpatient visits (not treatment administration related) (IRR = 1.19; P < 0.004), and a lower rate of
medical visits associated with treatment administration (IRR = 0.34; P < 0.001). There were no significant differences
between the two groups in total monthly healthcare costs ($11,920 vs. $11,898 for trastuzumab and lapatinib
patients, respectively; P = 0.451). Findings from our study show that, irrespective of the treatment initiated at index
date, disease management in patients with mBC is associated with similar and substantial healthcare costs. Any
differences in specific components of healthcare costs were associated with differences in the mode of treatment
administration. Approximately 50% of all costs were non-drug related, and future studies should focus on how these
costs may be controlled, regardless of mode of treatment administration.
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Metastatic breast cancer (mBC) is the second most fatal
cancer among women (Susan G Komen Foundation
2013). In 2014, 232,670 women are expected to be diag-
nosed with invasive breast cancer in the United States
(Siegel et al. 2014), and approximately 30% of all cases of
primary breast cancer are known to eventually metastasize
(Mayer 2011). Economically, mBC is known to impose a
substantial burden. Studies reporting the cost of mBC
treatment have noted costs ranging from ~ $7,500 per
month (calculated using data collected between 2000 and
2006) to ~ $10,000 per month (calculated in 2010 US
dollars) (Vera-Llonch et al. 2011; Montero et al. 2012).
The human epidermal growth factor receptor 2 (HER2)
protein is a common marker in mBC detection; the HER2
protein is known to signal cell growth and division and
thus to promote the growth of cancer cells. HER2-positive
tumors have been implicated in mBC (Guy et al. 1992),
with approximately 20% to 25% of all patients having
tumors that are HER2-positive (Slamon et al. 1987, 1989).
In addition, HER2-positive tumor status has been asso-
ciated with more aggressive disease, increased disease re-
currence, and a poor response to regular chemotherapy
(Borg et al. 1990; Kumar et al. 2007; Gullo et al. 2013).
Treatment goals for patients with mBC are to prolong
patient survival, and to minimize cancer-associated disease
symptoms, allowing stability or improvement in the pa-
tient’s quality-of-life. Prior to 2012, biological therapy, in-
cluding trastuzumab (Herceptin™, Genentech, Inc., South
San Francisco, CA, USA) and lapatinib (Tykerb™, Glaxo-
SmithKline, LLC, London, UK), was the primary treatment
option for patients with HER2-positive mBC. Trastuzumab
is a HER2 antagonist that binds directly to the protein re-
ceptor, and is recommended in combination with paclitaxel
for first line treatment, or as a single agent in patients who
have received one or more chemotherapy regimens for
metastatic disease (Slamon et al. 2001). Trastuzumab has
been shown to increase the clinical benefit of first-line
chemotherapy (Slamon et al. 2001). The other commonly
used biologic, lapatinib, is a tyrosine kinase inhibitor that
interrupts HER2 pathways, and is recommended in com-
bination with capecitabine in patients who have received
prior chemotherapy or in combination with letrozole in
postmenopausal women with hormone-receptor positive
metastatic breast cancer for whom hormonal therapy is in-
dicated (Medina and Goodin 2008; GlaxoSmithKline, LLC
2007). The National Cancer Commission Network (NCCN)
guidelines recommend trastuzumab or lapatinib as the pre-
ferred treatment agents for recurrent or metastatic HER2-
positive BC (National Comprehensive Cancer Network
2012). Administration of the two agents differs, as lapatinib
is orally-administered, while trastuzumab must be admi-
nistered by a healthcare professional as an intravenous infu-
sion (GlaxoSmithKline, LLC 2007; Genentech, Inc. 2006).No studies have compared the clinical and economic
outcomes associated with trastuzumab- versus lapatinib-
based treatments in mBC in a real-world setting. Given
that trastuzumab and lapatinib have different mechanisms
of action and administration, it is unclear whether these
two drugs will be associated with similar treatment pat-
terns, healthcare resource utilization (HRU), and health-
care costs. The objective of this study is, therefore, to
compare treatment discontinuation, HRU, and healthcare
costs among patients with mBC initiated on trastuzumab
versus lapatinib in a real world setting.
Patients and methods
Data source
The study was conducted using data from the PharMetrics®
Integrated Database (PharMetrics) from 2000–2011. The
PharMetrics database comprises medical and drug claims
for more than 70 million members from over 100 health-
care plans, covering all census regions of the United States,
with a concentration in the southern and midwestern
regions. Data contained within the database include patient
demographics, healthcare plan enrollment, diagnoses and
procedures, and drug prescription dispensing claims (Phar-
Metrics 2011). Data are de-identified and comply with the
patient requirements of the Health Insurance Portability
and Accountability Act (HIPAA). Therefore, Institutional
Review Board approval was not required.
Patient selection and study design
Eligible patients were included in the study if they: (1)
initiated trastuzumab or lapatinib on or after March 13,
2007 (the FDA approval date of lapatinib); (2) had at
least two independent secondary malignant neoplasm
diagnoses (ICD-9-CM: 197.xx, 198.xx) within 90 days,
occurring prior to or on the date of trastuzumab or lapa-
tinib initiation; (3) had at least two BC diagnoses (ICD-
9-CM: 174.x) during the 365 days prior to, and up to
90 days following, the first mBC diagnosis — with at
least one during the 365 days prior to the first mBC
diagnosis; and (4) were continuously enrolled in their
healthcare plan for at least 6 months prior to, and at
least 30 days following, the trastuzumab or lapatinib ini-
tiation date. Patients with mBC were excluded from the
study if they had a diagnosis for any other cancer prior
to the first BC diagnosis, or of if they used trastuzumab
and lapatinib concomitantly within the first 28 days
following treatment initiation (Figure 1).
Patients who met the above sample selection criterion
were classified into two mutually exclusive cohorts based
on the first drug initiated on or after March 13, 2007
(the FDA approval date for lapatinib): (1) trastuzumab
patients; and (2) lapatinib patients. The first prescription
fill date/therapy administration date was defined as the
index date.
365 days
Disease Index Date 
First diagnosis of a secondary malignant 
neoplasm
End of health plan 
continuous eligibility or 
end of data availability
90 days
Study Index Date 
First prescription for 
trastuzumab (trastuzumab 
users) or lapatinib (lapatinib 
users)
Baseline Period
Continuous health plan 
enrollment for ≥180 days
Follow-up Period
Continuous health plan
enrollment for ≥30 days
≥2 diagnoses for a secondary 
malignant neoplasm within  ≤ 90 
days
First Claim for Breast Cancer 
Diagnosis
Patients did not have any cancer 
diagnoses before the first breast 
cancer diagnosis
≥1 diagnosis of breast cancer within ≤365 days 
before the first diagnosis of secondary malignant 
neoplasm and 
≥1 diagnosis of breast cancer within ≤365 days 
before or ≤90 days after the first diagnosis of 
secondary malignant neoplasm
2nd BC diagnosis up to 90 
days after the disease 
index date
Figure 1 Sample selection.
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used to compare outcomes between patients who initiated
trastuzumab and lapatinib. The baseline period was de-
fined as the 6-month period prior to the index date. The
study period spanned from the index date up to the end
of healthcare plan enrollment or the end of data availabil-
ity, whichever occurred first.
Outcomes and statistical analyses
Measures and study outcomes
Patient characteristics. Baseline characteristics included
the following: demographic data (age and geographic re-
gion); index year; time from the first mBC diagnosis to
the index date; the Charlson Comorbidity Index (CCI)
findings (Quan et al. 2005); physical and mental comor-
bidities (Elixhauser et al. 1998); prior cancer treatments;
HRU; and costs at baseline. Study period characteristics
included the number of days between the index date and
the end of the study period; the number of days between
the index date and treatment discontinuation or the end
of the study, whichever occurred first; and cancer treat-
ments used during the study period.
Treatment discontinuation was defined as the first
interruption of the index drug for at least 45 consecutive
days (the interruption may have occurred between the
end of one prescription fill/infusion and the start of the
next prescription fill/infusion, or between the end of one
prescription fill/infusion and the end of the study
period). The discontinuation date was defined as the last
day of supply before the treatment discontinuation.HRU during the study period was identified using med-
ical claims, and was reported for the following categories:
inpatient admission, inpatient days, emergency room
visits, outpatient visits, medical services associated with
treatment administration, and other medical services (e.g.
laboratory, radiology, ancillary services). The category
“medical services associated with treatment admini-
stration” was defined as medical visits associated with a
procedure for treatment administration by a health care
professional (e.g., injection or infusion of medications).
Healthcare costs incurred during the study period were
reported from a payer’s perspective. As the duration of
the observation periods varied across patients, costs
were reported as monthly costs. Healthcare costs were
adjusted for inflation using the consumer price index for
medical categories and expressed in 2012 U.S. dollars.
Healthcare cost categories included inpatient costs, out-
patient costs, emergency room costs, other medical ser-
vice costs, and total medical costs. We also examined
medical costs associated with treatment administration,
drug-only cost, and total drug costs. Total healthcare
costs were defined as the sum of total medical costs and
total drug costs.
Sensitivity analysis (prior trastuzumab patients)
A large proportion of lapatinib patients (65.3%) were
treated with trastuzumab prior to the index date, which
was either in the adjuvant or metastatic setting. This
may indicate that lapatinib patients have a different se-
verity and treatment profile. Accordingly, a sensitivity
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stratified based on prior trastuzumab use into two mu-
tually exclusive cohorts: (1) lapatinib patients with prior
trastuzumab use; and (2) lapatinib patients without prior
trastuzumab use. Each cohort was compared to tras-
tuzumab patients regarding each of the above study
outcomes.
Statistical analyses
Patient characteristics were compared using Wilcoxon
rank-sum tests for continuous variables and chi-square
tests for categorical variables.
Discontinuation rates for lapatinib and trastuzumab
patients were estimated using Kaplan-Meier survival
analyses and were then compared between the two
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founding factors) cost differences between lapatinib and
trastuzumab patients were estimated using GLM with a
log link and gamma distribution or were calculated
using two-part models for cost categories when > 5% of
the observations had a cost of $0 (where the first part is
a logistic model and the second part is a GLM model
with a log link and a gamma distribution). P-values were
estimated using non-parametric bootstrap resampling
techniques of 499 iterations.
For all outcomes, multivariate analyses were used to
adjust for potential confounding factors. Covariates
were selected based on baseline variables with statis-
tically significant differences between the two study co-
horts, and with at least 5% prevalence in each cohort,
and included baseline demographics (age, region of resi-
dence), index year, chemotherapy or anti-angiogenic useTable 1 Baseline characteristics: demographics and prior ther
Characteristics
Total number of patients











Time from first mBC diagnosis to index date (days; mean ± SD)
Prior cancer treatments, N (%)
Trastuzumab use, any time prior to the index date
Hormonal therapy, during the baseline period
Radiation therapy, during the baseline period
Surgery (mastectomy), during the baseline period
Chemotherapy or anti-angiogenic therapy, during the baseline period
Chemotherapy or biological therapy, between the first mBC diagnosis and
CCIa (mean ± SD)




**Denotes statistical significance at the 5% level.
aCCI, Charlson Comorbidity Index.
bOnly comorbidities with at least 5% prevalence in each cohort that were statistical
were reported.
N, number of patients; SD, standard deviation.during the baseline period, radiation therapy use during
the baseline period, baseline HRU, and time from first
mBC diagnosis to index date.
All statistical analyses were carried out with SAS




Overall, 643 patients met the inclusion criteria, of which
381 initiated trastuzumab, and 262 initiated lapatinib
(Figure 2). Trastuzumab patients were older than lapatinib
patients (56.7 vs. 54.4; P = 0.020), and a greater proportion
of trastuzumab patients were from the southern region of
the United States (39.6% vs. 28.2%; P = 0.003), while a
greater proportion of lapatinib patients were from the
midwestern area (38.5% vs. 30.7%; P = 0.039; Table 1).apies
Trastuzumab Lapatinib P-value
N = 381 N = 262
56.7 ± 12.0 54.4 ± 10.2 0.020**
74 (19.4) 63 (24.0) 0.159
117 (30.7) 101 (38.5) 0.039**
151 (39.6) 74 (28.2) 0.003**
39 (10.2) 24 (9.2) 0.652
101 (26.5) 98 (37.4) 0.003**
131 (34.4) 78 (29.8) 0.220
89 (23.4) 46 (17.6) 0.076
60 (15.7) 40 (15.3) 0.869
185.8 ± 329.4 518.5 ± 490.6 < 0.001**
- 171 (65.3)
104 (27.3) 61 (23.3) 0.252
104 (27.3) 103 (39.3) 0.001**
61 (16.0) 7 (2.7) < 0.001**
114 (29.9) 154 (58.8) < 0.001**
index date 118 (31.0) 188 (71.8) < 0.001**
6.7 ± 1.0 6.6 ± 1.2 0.224
22 (5.8) 28 (10.7) 0.022**
49 (12.9) 19 (7.3) 0.023**
64 (16.8) 70 (26.7) 0.002**
ly significantly different between lapatinib and trastuzumab patients
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diagnosis to index date (185.8 days vs. 518.5 days;
P < 0.001). A greater proportion of lapatinib patients re-
ceived chemotherapy or anti-angiogenic therapy during
the baseline period (29.9% vs. 58.8%, P < 0.001) and had
used chemotherapy or biologic therapy between the first
mBC diagnosis and the index date (71.8% vs. 31.0%;
P < 0.001). The majority (65.3%) of lapatinib patients had
used trastuzumab prior to the index date.
With respect to comorbidities during the baseline
period, trastuzumab patients had a higher prevalence of
chronic pulmonary diseases (12.9% vs. 7.3%; P = 0.023),
and lapatinib patients had a higher prevalence of neuro-
logical diseases (10.7% vs. 5.8%; P = 0.022) and anemia
(26.7% vs. 16.8%; P = 0.002).
During the baseline period, trastuzumab patients had
fewer outpatient visits and lower associated costsTable 2 Description of therapies used during the study period
Number of days between the index date and the end of the study period, m
Treatment duration (i.e. the number of days between the index date and tre
discontinuation or the end of the study period), mean ± SD




Chemotherapy or anti-angiogenic therapy, N (%)

















Any chemotherapy or anti-angiogenic therapy within 28 days following the
**Denotes statistical significance at the 5% level.
aAny chemotherapy or anti-angiogenic therapy during the study period or at the in
bNeither etoposide nor vinblastine were prescribed during the study period.
N, number of patients; SD, standard deviation.(22.0 vs. 26.3, P < 0.001; $16,662 vs. $26,572, P = 0.006),
fewer medical visits and costs associated with treatment
administration (5.1 vs. 7.6, P < 0.001; $6,153 vs. $16,179,
P < 0.001), lower total drug costs ($1,840 vs. $4,598,
P < 0.001), and lower total healthcare costs ($38,655 vs.
$64,261, P < 0.001).
Compared to lapatinib patients, trastuzumab patients
had a longer treatment duration (i.e., the number of days
between the index date and treatment discontinuation or
the end of the study period) (269.1 days vs. 179.8 days;
P < 0.001) (Table 2). A greater proportion of trastuzumab
patients were prescribed hormonal therapy (28.9% vs.
9.5%; P < 0.001), and underwent mastectomy (8.7% vs.
0.8%; P < 0.001; Table 2) over the study period. The
majority of trastuzumab (84.0%) and lapatinib patients
(87.0%) were co-prescribed chemotherapy or anti-angio-
genic agents during the study period.: trastuzumab patients versus lapatinib patients
Trastuzumab Lapatinib P-value
N = 381 N = 262
ean ± SD 453.3 ± 334.0 412.9 ± 327.1 0.123
atment 269.1 ± 235.1 179.8 ± 189.0 < 0.001**
110 (28.9) 25 (9.5) < 0.001**
168 (44.1) 114 (43.5) 0.884
33 (8.7) 2 (0.8) < 0.001**
320 (84.0) 228 (87.0) 0.287
71 (18.6) 194 (74.0) < 0.001**
156 (40.9) 48 (18.3) < 0.001**
112 (29.4) 21 (8.0) < 0.001**
103 (27.0) 25 (9.5) < 0.001**
86 (22.6) 40 (15.3) 0.022**
51 (13.4) 26 (9.9) 0.184
29 (7.6) 28 (10.7) 0.178
38 (10.0) 21 (8.0) 0.398
39 (10.2) 12 (4.6) 0.009**
17 (4.5) 5 (1.9) 0.080
15 (3.9) 15 (5.7) 0.291
8 (2.1) 0 (0.0) -
2 (0.5) 3 (1.1) 0.379
1 (0.3) 1 (0.4) 0.790
0 (0.0) 0 (0.0) -
0 (0.0) 0 (0.0) -
index date 285 (74.8) 193 (73.7) 0.745
dex date.
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During the study period, 63.4% of lapatinib patients and
48.3% of trastuzumab patients discontinued treatment.
After adjusting for confounders, lapatinib patients had a
risk of treatment discontinuation that was 57% higher
than that of trastuzumab patients (HR 1.57, 95% CI
1.22-2.03; P < 0.001; Figure 3).
After adjusting for confounders, lapatinib patients had
a higher incidence of outpatient visits (IRR 1.19, 95% CI
1.06-1.34; P = 0.004; Figure 4), and a lower incidence of
medical visits that were associated with treatment
administration (IRR 0.34, 95% CI 0.29-0.41; P < 0.001;
Figure 4). There were no statistically significant diffe-
rences found for inpatient, emergency room, or other
medical service visits between trastuzumab patients and
lapatinib patients.
After adjusting for confounders, results showed that
overall there was no statistically significant difference in
the total healthcare cost incurred by lapatinib versus
trastuzumab patients (Figure 5). On average, patients in
both cohorts had a total monthly healthcare cost of
approximately $12,000. Although lapatinib patients in-
curred higher outpatient costs ($3,639 vs. $2,756, adjusted
difference = $847; P = 0.104; Figure 6) and drug-only costs
($3,279 vs. $571, adjusted difference = $2,676; P < 0.001;
Figure 7), this was balanced by the higher medical cost
associated with treatment administration incurred by
trastuzumab patients ($6,167 vs. $1,547, adjusted diffe-
rence = $4,904; P < 0.001; Figure 7). This higher medical
cost for treatment administration led to higher total drug
costs among trastuzumab patients ($6,738 vs. $4,825, ad-
justed difference = $1,714; P < 0.001; Figure 7). There was
no significant difference in total medical service costs,Index drug N 1-Month Rates: 3-Month Rates:
Lapatinib: 262 10.69 (7.51 - 15.10) 32.19 (26.73 - 38.4
Trastuzumab: 381 6.04 (4.05 - 8.95) 12.31 (9.33 - 16.15
Log-Rank Test: <.0001
HR=1.57, 95% CI
Figure 3 Comparison of discontinuation rates between patients initiainpatient costs, emergency room costs, and other medical
service costs between study cohorts (Figure 6).
Sensitivity analysis
Overall, findings from the sensitivity analysis were con-
sistent with the main analysis (results not reported). Few
differences were found for HRU and healthcare costs,
wherein (1) lapatinib patients without prior trastuzumab
use had a higher incidence of inpatient admissions (IRR
1.74, P = 0.002) compared to trastuzumab patients; (2)
the comparison between lapatinib patients with prior
trastuzumab use and trastuzumab patients was no lon-
ger statistically significant for outpatient visits; and (3)
lapatinib patients without prior trastuzumab use expe-
rienced higher medical service costs when compared to
trastuzumab patients by $3,825 (P < 0.001).
Discussion
Findings from this study indicate that mBC patients in-
curred substantial healthcare costs irrespective of the
index treatment (i.e., lapatinib or trastuzumab). Overall,
patients incurred an average monthly total healthcare
cost of approximately $12,000 per patient per month.
This finding is consistent with previous studies that re-
ported average healthcare costs ranging from ~ $7,500
per month to ~ $10,000 per month (Kumar et al. 2007;
Gullo et al. 2013). In our study, although the two groups
had similar total monthly costs, the cost drivers for lapa-
tinib and trastuzumab patients were different: while 57%
of trastuzumab user costs resulted from total drug costs,
59% of lapatinib user costs resulted from total medical
service costs. Non-drug costs accounted for appro-
ximately half of the total costs (43% and 59% for6-Month Rates: 12 -Month Rates: 24-Month Rates:
3) 46.19 (39.88 - 53.00) 75.89 (69.01 - 82.22) 90.97 (82.79 - 96.26)
) 25.21 (20.84 - 30.31) 46.28 (40.48 - 52.49) 75.50 (68.51 - 81.94)
 (1.22-2.03), P=0.0005
ted on trastuzumab and patients initiated on lapatinib.
Figure 4 One-year incidence rates for each category of HRU.
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though total drug costs were greater among trastuzumab
patients due to treatment administration costs, total
costs were not statistically significantly different among
the two patient groups due to the higher medical service
costs incurred by lapatinib patients. Lapatinib and tras-
tuzumab patients were also generally comparable inFigure 5 Average monthly total healthcare costs.terms of HRU, except for the incidence of outpatient
visits, which was higher in lapatinib patients, and the
incidence of medical visits associated with treatment ad-
ministration, which was higher in trastuzumab patients.
The higher costs for medical visits associated with treat-
ment administration in trastuzumab patients are mainly
explained by the method of administration of trastuzumab,
Figure 6 Average monthly total medical costs.
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as an intravenous infusion.
The findings of this study also show that trastuzumab
patients were more persistent in continuing treatment
than the patients receiving lapatinib. Improved treatmentFigure 7 Average monthly total drug costs.persistence, which is essential to treatment adherence,
may be somewhat surprising in this case, as lapatinib is an
oral medication and therefore presumably convenient
to take. Trastuzumab patients may, however, be more
persistent because of closer clinical follow-up, as clinical
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lyses are warranted to better understand the reasons for
discontinuation and the factors impacting persistence
among patients treated with trastuzumab versus lapatinib.
The FDA recently approved two new therapies for
HER2-positive mBC: (1) pertuzumab (Perjeta™, Genentech,
Inc.), a HER2 receptor antagonist, indicated in combi-
nation with trastuzumab and docetaxel in HER2-positive
patients who have not received prior anti-HER2 therapy or
chemotherapy for metastatic disease (Genentech, Inc.
2012); and (2) ado-trastuzumab emtansine (Kadcyla™,
Genentech, Inc.), a HER-targeted antibody and micro-
tubule inhibitor conjugate, indicated as a single agent for
the treatment of patients with HER2-positive mBC who
have received prior therapy for mBC or who have deve-
loped disease recurrence within 6 months of completing
adjuvant therapy (Genentech, Inc. 2013). Due to their re-
cent approval at the time the study was conducted and the
limited data availability, these two mBC therapies were not
included in the scope of this study.
This study was subject to common limitations of
retrospective administrative database studies. First, lapa-
tinib patients may have been more severely ill, given
their prior trastuzumab use and longer time to initial
treatment of targeted therapy; however, the claims data-
base did not contain information on disease severity. We
attempted to control for severity by adjusting for obser-
vable variables, such as the time between the first mBC
diagnosis and the index date, comorbidities, baseline
healthcare utilization and costs, and the use of other
cancer treatments prior to the index date. Prior trastu-
zumab use may also be an indicator of disease severity,
and, consequently, we investigated this possibility by
stratifying patients based on prior trastuzumab use.
Retrospective databases are also subject to coding errors
or data omissions; however, these are expected to affect all
treatment cohorts to a similar extent and are unlikely to
alter conclusions.
An additional limitation of this study is that it did not
distinguish between the patient’s lines of therapy (first, se-
cond, third, etc.). The ideal cost and HRU comparison
would be made between trastuzumab patients and lapati-
nib patients without prior therapy use; however the sample
size was too restrictive. Therefore, we conducted a sensiti-
vity analysis stratified by prior trastuzumab use, and found
robust results. Sensitivity analyses comparing outcomes
between lapatinib patients with and without prior trastuzu-
mab use versus trastuzumab patients demonstrated that
results were generally consistent with those from the main
analysis (i.e., regardless of prior trastuzumab use, lapatinib
use was associated with similar HRU, total healthcare
costs, and greater treatment discontinuation). Prior trastu-
zumab use seems to be associated with an unexpected
benefit, since lapatinib patients without prior trastuzumabtreatment experienced a greater number of inpatient visits,
while the same effect was not observed for lapatinib pa-
tients with prior trastuzumab use. Lapatinib patients with-
out prior trastuzumab use were also found to have higher
medical service costs, as compared to trastuzumab pa-
tients. Finally, the study sample was limited to privately in-
sured employees or their dependents diagnosed with mBC,
and who whom the main subscriber remained employed for
the duration of the study period; thus, these findingsmay not
be generalizable to the overall population of patients with
mBC. Nonetheless, claims data remain a valuable source
of information, as they comprise a valid, large sample
reflecting patients’ behavior in a real-world setting.
In conclusion, findings from our study show that, irre-
spective of the treatment initiated at the index date, dis-
ease management in patients with mBC is associated with
similar and substantial healthcare costs in both cohorts,
with the only observed healthcare cost differences stem-
ming from differences in mode of treatment administra-
tion, and with non-drug costs accounting for an average
of 48.5% of total costs. Patients initiated on lapatinib had
higher rates of treatment discontinuation, more outpatient
visits not related to treatment administration, and fewer
medical visits associated with treatment administration.
Prior trastuzumab use in lapatinib patients suggests that
lapatinib patients may have experienced a more severe
disease course. However, results from the sensitivity ana-
lyses that take into account this prior use were generally
consistent with findings from the main analysis and do
not change the overall study conclusion.
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